National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria

Cover Page

Cite item

Full Text

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal blood disorder caused by somatic mutation of the phosphatidylinositol
glycan complementation group A gene (PIG-A) in a hematopoietic stem cell. PNH is characterized by chronic intravascular hemolysis, bone marrow failure, thrombosis, renal dysfunction and other severe clinical syndromes. These clinical guidelines include definition, classification, methods and diagnostic criteria of PNH, indications for screening, optimal treatment including targeted therapy with eculizumab, bone marrow transplantation and symptomatic therapy.

About the authors

A. D. Kulagin

First I.P. Pavlov State Medical University of St.‑Petersburg, Ministry of Health of Russia

Author for correspondence.
Email: kulagingem@rambler.ru
Russian Federation

I. A. Lisukov

I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg

Russian Federation

V. V. Ptushkin

Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow

Russian Federation

Ye. R. Shilova

Russian Research Institute of Hematology and Transfusiology, Russian Federal Biomedical Agency, Saint Petersburg

Russian Federation

N. V. Tsvetaeva

Hematology Research Center, Ministry of Health of Russia, Moscow

Russian Federation

Ye. A. Mikhailova

Hematology Research Center, Ministry of Health of Russia, Moscow

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.